Table 1.

Clinical and Demographic Characteristics of the Statin and Control Groups

	Statin Group	Control Group	p
n	53	61
Age (years)	65.7 ± 9.0	67.0 ± 8.3	0.40
Duration of statin treatment (months)	20 ± 17
Cardiovascular risk factors
Male sex	42 (79%)	45 (74%)	0.64
Coronary artery disease	13 (25%)	6 (10%)	0.07
Arterial Hypertension	39 (74%)	49 (80%)	0.53
Diabetes mellitus	15 (28%)	14 (23%)	0.66
Current cigarette smoking	31 (58%)	38 (62%)	0.82
Medical treatment
ACE inhibitors	22 (41%)	22 (36%)	0.69
ARBs	10 (19%)	13 (21%)	0.93
Beta-blockers	18 (38%)	14 (23%)	0.27
Calcium channel blockers	15 (34%)	27 (44%)	0.12
Diuretics	10 (19%)	21 (34%)	0.08
Clopidogrel	22 (42%)	24 (39%)	0.91
Aspirin	23 (43%)	29 (48%)	0.67
Diabetes mellitus (oral drugs)	12 (22%)	10 (16%)	0.61
Diabetes mellitus (insulin)	2 (4%)	3 (5%)	0.91
Presence/absence of symptoms
Symptomatic	28 (53%)	31 (51%)	0.86
Amaurosis Fugax	1 (2%)	2 (3%)	0.93
Transient Ischemic Attacks	22 (42%)	23 (38%)	0.95
Ischemic Stroke	5 (9%)	6 (10%)	0.86
Asymptomatic	25 (47%)	32 (52%)	0.57
Serum parameters
Total Cholesterol (mg/dl)	176 ± 49	202 ± 40	0.011
Low-density lipoprotein (mg/dl)	103 ± 46	127 ± 34	<0.001
High-density lipoprotein (mg/dl)	38 ± 6	42 ± 10	0.16
Triglyceride (mg/dl)	159 ± 109	154 ± 66	0.86
Apolipoprotein A (mg/dl)	111 ± 21	118 ± 24	0.23
Apolipoprotein B (mg/dl)	89 ± 30	96 ± 26	0.11
Lipoprotein (a) (mg/dl)	48 ± 52	41 ± 29	0.87
Homocysteine (µmol/l)	10.4 ± 3.7	13.0 ± 5.1	0.07
Creatinine (mg/dl)	1.00 ± 0.44	1.03 ± 0.47	0.58

ACE, Angiotensin converting enzyme; ARBs, Angiotensin receptor blockers.